Weleader Biomedical Co (ROCO:7713) Long-Term Debt: NT$491 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
42 GF Score
Price NT$70.00
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Long-Term Debt?

Weleader Biomedical Co ROCO:7713 42 Long-Term Debt is NT$491 Mil as of Mar. 2026. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review.

Weleader Biomedical Co's Long-Term Debt for the quarter that ended in Mar. 2026 was NT$491 Mil.

Weleader Biomedical Co's quarterly Long-Term Debt declined from Sep. 2025 (NT$489 Mil) to Dec. 2025 (NT$488 Mil) but then increased from Dec. 2025 (NT$488 Mil) to Mar. 2026 (NT$491 Mil).

Weleader Biomedical Co's annual Long-Term Debt increased from Dec. 2023 (NT$249 Mil) to Dec. 2024 (NT$398 Mil) and increased from Dec. 2024 (NT$398 Mil) to Dec. 2025 (NT$488 Mil).

Weleader Biomedical Co  (ROCO:7713) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Weleader Biomedical Co Long-Term Debt Related Terms

Weleader Biomedical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Long-Term Debt Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 18.65 270.23 249.03 397.96 488.43

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 393.09 387.20 488.51 488.43 490.98
ROCO:7713
42GF Score
Weleader Biomedical Co Ltd ROCO:7713
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$491 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a Long-Term Debt of NT$491 Mil as of Mar. 2026.
Is Weleader Biomedical Co's Long-Term Debt too high?
Weleader Biomedical Co's current Long-Term Debt is NT$491 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Long-Term Debt compare to ABT and SYK?
Weleader Biomedical Co's Long-Term Debt of NT$491 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Weleader Biomedical Co's current Long-Term Debt is NT$491 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Long-Term Debt of NT$491 Mil. The current Long-Term Debt is NT$491 Mil. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Long-Term Debt is NT$491 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score

Get the complete analysis for ROCO:7713

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.00
Price